-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Initiates Coverage On Viking Therapeutics with Overweight Rating, Announces Price Target of $104

Benzinga·04/28/2025 20:43:10
Listen to the news
Cantor Fitzgerald analyst Steven Seedhouse initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Overweight rating and announces Price Target of $104.